Overview

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Status:
Active, not recruiting

Trial end date:
2026-01-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive bladder cancer (MIBC).

Phase:

Phase 2

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Gemcitabine
Pembrolizumab